A randomised controlled trial comparing GnRH antagonist Cetrorelix with GnRH agonist Leuprorelin for endometrial thinning prior to transcervical resection of endometrium

Kalsang Bhatia, Y Doonan, Andreas Giannakou, Bernard Bentick
In: BJOG: An International Journal of Obstetrics & Gynaecology · 2008 · vol. 115(10) , pp. 1214–1224 · doi:10.1111/j.1471-0528.2008.01837.x · PMID:18715405 · W1964225687
article OA: closed CC0 ⤵ 2 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-13 ⓘ

This randomized controlled trial found that leuprorelin achieved more consistent endometrial thinning than cetrorelix prior to transcervical resection of the endometrium, despite similar amenorrhea rates.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVES: To compare the effectiveness of leuprorelin and cetrorelix, when used as preoperative endometrial thinning agents prior to transcervical resection of endometrium (TCRE). DESIGN: A prospective, double-blind randomised controlled trial. SETTING: Gynaecological department of a UK district general hospital. PARTICIPANTS: A total of 106 premenopausal women with dysfunctional uterine bleeding, undergoing TCRE. INTERVENTIONS: Women were equally randomised to 3.75 mg of leuprorelin acetate (3-4 weeks) or 3 mg cetrorelix (4-7 days) prior to TCRE. About 1 ml saline was given as placebo in both arms. MAIN OUTCOME MEASURES: Amenorrhoea rate at 6 months, endometrial thickness using transvaginal ultrasound on the day of operation. RESULTS: A total of 100 women completed the trial with no loss to follow up. Amenorrhoea rate at 6 months after surgery was high in both groups (80% cetrorelix and 84% leuprorelin) with no statistical significance. All endometrial outcome measures including endometrial thickness on ultrasound, histology and operative appearance were more favourable in leuprorelin group as compared with cetrorelix (P values 0.013, <0.001 and 0.003 respectively). More women in leuprorelin group had hot flushes as compared with cetrorelix (15/50 versus 6/50; P = 0.047). No significant differences were seen in other outcome measures. CONCLUSIONS: In dosages used, leuprorelin produced more consistent thinning of the endometrium as compared with cetrorelix, although this did not make any significant difference to operative or menstrual outcomes. The endometrial thinning effect with cetrorelix does appear to be more favourable than that seen at postmenstrual phase in other studies. The optimum (possibly higher) dosage of cetrorelix for this purpose has not yet been established.

My notes (saved in your browser only)

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (19)

Cited by (2)

Source provenance

openalex
last seen: 2026-05-11T06:14:16.517584+00:00
License: CC0 · commercial use OK